February 20, 2020
PhRMA Japan Executive Committee Chair Chris Hourigan Japan should limit the scope of its planned “off-year” re-pricing to off-patent drugs and not apply its healthcare technology assessment (HTA) scheme to reimbursement decisions, the Pharmaceutical Research and Manufacturers of America (PhRMA)...read more